First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.
Priska KaufmannMarion OrtGeorg GolorRüdiger KornbergerJasper DingemansePublished in: British journal of clinical pharmacology (2020)
ACT-539313 exhibits good safety and tolerability at single doses of up to and including 400 mg that warrant further investigations.